Providence Health & Services
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1859-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.providence.org
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 110
- Registration Number
- NCT06719362
- Locations
- 🇺🇸
Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 12
- Registration Number
- NCT06353997
- Locations
- 🇺🇸
Ellison Institute of Technology (EITM), Los Angeles, California, United States
🇺🇸Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
🇺🇸Providence St. Vincent Medical Center, Portland, Oregon, United States
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 28
- Registration Number
- NCT06175000
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Providence Health & Services; Providence Neurological Specialties, Portland, Oregon, United States
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
- Conditions
- Metastatic MelanomaHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 92
- Registration Number
- NCT05913388
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Clinical Outcomes and Patient Satisfaction With Use of the Amma System
- Conditions
- Breast Cancer
- Interventions
- Device: Amma Cooling Caps
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 15
- Registration Number
- NCT05508984
- Locations
- 🇺🇸
Providence Cancer Institute - Newberg Clinic, Newberg, Oregon, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸Providence Oncology and Hematology Care - Westside, Portland, Oregon, United States
Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors
- Conditions
- KRAS G12V Mutant Advanced Epithelial Cancers
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Providence Health & Services
- Registration Number
- NCT05389514
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
- Conditions
- Malignant Epithelial Neoplasms
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 1
- Registration Number
- NCT05349890
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
- Conditions
- Melanoma, Uveal
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 6
- Registration Number
- NCT05308901
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
- Conditions
- Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 6
- Registration Number
- NCT05249114
- Locations
- 🇺🇸
Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
- Conditions
- Refractory Cutaneous Melanoma
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 4
- Registration Number
- NCT05200143
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States